Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Nomoto K
Department of Immunology, Kyushu University, Fukuoka, Japan.
Eur J Immunol. 1990 Sep;20(9):2005-13. doi: 10.1002/eji.1830200919.
Mechanisms of cyclophosphamide (CY)-induced tolerance were studied. When C3H/He Slc (C3H; H-2k, Mls-1b) mice were primed i.v. with 1 x 10(8) viable spleen cells from H-2-identical AKR/J Sea (AKR; H-2k, Mls-1a) mice and treated with 200 mg/kg of CY 2 days later, a long-lasting skin allograft tolerance to AKR was established. When [C57BL/6 Sea (B6; H-2b, Mls-1b) x AKR]F1 (B6AKF1) cells were used as the tolerogen, however, only a moderate, but not long-lasting, skin tolerance to AKR was observed. In the C3H mice treated with AKR cells and CY, the intrathymic clonal deletion of V beta 6+ T cells, which are strongly correlated with reactivity to Mls-1a antigens, was observed in the chimeric thymus on day 35, although neither the clonal deletion of V beta 6-bearing T cells nor the mixed chimerism was observed in the thymus on day 14. In the C3H mice treated with B6AFKF1 cells followed by CY, however, neither the clonal deletion of V beta 6+ T cells nor the mixed chimerism was observed in the thymus throughout the test period. In the lymph nodes of the C3H mice treated with AKR cells and CY, only CD4+ V beta 6+ T cells, bur not CD8+V beta 6+ T cells, had selectively decreased by day 14, and they were hardly detectable on day 35. The selective decrease of CD4+V beta 6+ T cells in the lymph nodes was also observed by day 14 when B6AKF1 cells were used as the tolerogen, although CD4+V beta 6+ T cells gradually increased on day 35, at which time almost all skin grafts from AKR had already been rejected. These results strongly support the necessity of the intrathymic mixed chimerism and clonal deletion of donor-reactive T cells for a long-lasting skin allograft tolerance in CY-induced tolerance.
研究了环磷酰胺(CY)诱导耐受的机制。当C3H/He Slc(C3H;H-2k,Mls-1b)小鼠经静脉注射来自H-2相同的AKR/J Sea(AKR;H-2k,Mls-1a)小鼠的1×10⁸个活脾细胞进行致敏,并在2天后用200mg/kg的CY处理时,建立了对AKR的持久皮肤同种异体移植耐受。然而,当使用[C57BL/6 Sea(B6;H-2b,Mls-1b)×AKR]F1(B6AKF1)细胞作为致耐受原时,仅观察到对AKR的中度但非持久的皮肤耐受。在用AKR细胞和CY处理的C3H小鼠中,在第35天嵌合胸腺中观察到Vβ6⁺T细胞的胸腺内克隆缺失,这与对Mls-1a抗原的反应性密切相关,尽管在第14天胸腺中未观察到携带Vβ6的T细胞的克隆缺失或混合嵌合现象。然而,在用B6AFKF1细胞继以CY处理的C3H小鼠中,在整个测试期间胸腺中均未观察到Vβ6⁺T细胞的克隆缺失或混合嵌合现象。在用AKR细胞和CY处理的C3H小鼠的淋巴结中,到第14天时仅CD4⁺Vβ6⁺T细胞选择性减少,而CD8⁺Vβ6⁺T细胞未减少,并且在第35天时几乎检测不到。当使用B6AKF1细胞作为致耐受原时,在第14天也观察到淋巴结中CD4⁺Vβ6⁺T细胞的选择性减少,尽管CD4⁺Vβ6⁺T细胞在第35天时逐渐增加,此时来自AKR的几乎所有皮肤移植均已被排斥。这些结果有力地支持了胸腺内混合嵌合以及供体反应性T细胞的克隆缺失对于CY诱导耐受中持久皮肤同种异体移植耐受的必要性。